StocksMedium•10 November 2026•
1 min read
Beam Therapeutics Reports Positive risto-cel Data and Plans 2026 BLA Filing
Key Facts
1The BEACON Phase 1/2 trial of risto-cel met its primary efficacy endpoint of freedom from severe vaso-occlusive crises (VOCs) for 12 consecutive months.
2The company plans to submit a Biologics License Application (BLA) in the U.S. as early as year-end 2026.
The BEACON Phase 1/2 trial of risto-cel met its primary efficacy endpoint of freedom from severe vaso-occlusive crises (VOCs) for 12 consecutive months, Beam Therapeutics Inc. announced. GlobeNewswire reported that the interim analysis confirmed the treatment successfully prevented severe VOCs while meeting all safety protocols, and the company plans to submit a Biologics License Application (BLA) in the U.S. as early as year-end 2026.
BEAM closed at $27.02 on November 9, 2026, prior to the release of the clinical data. The stock traded between a low of $25.96 and a high of $27.39 during that session, as the positive trial results now provide a clear regulatory filing path for the sickle cell disease treatment.